Taiho “Primed And Ready To Go” With Colon Cancer Drug Lonsurf
This article was originally published in The Pink Sheet Daily
After fast approval of oral chemotherapy combination Lonsurf for late-line colon cancer, U.S. oncology newcomer and Otsuka Holdings subsidiary plans to launch within two weeks at a reasonable price, says CEO Eric Benn.
You may also be interested in...
Solid tumor-focused Taiho Oncology teams with hematological cancer specialist Astex under the Otsuka umbrella. Taiho also performs US/Canada commercialization for all three firms.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.